BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Sign Up to like & getrecommendations! Published in 2019 at "European urology"
DOI: 10.1016/j.eururo.2018.09.020
Abstract: BACKGROUND Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk of recurrence in NMIBC patients receiving standard treatment.… read more here.
Keywords: risk; celecoxib; recurrence; high risk ... See more keywords
What to do during Bacillus Calmette–Guérin shortage? Valid strategies based on evidence
Sign Up to like & getrecommendations! Published in 2018 at "Current Opinion in Urology"
DOI: 10.1097/mou.0000000000000544
Abstract: Purpose of review Over the last decade, the world has experienced health-threatening supply shortages of Bacillus Calmette–Guérin (BCG) immunotherapy for nonmuscle-invasive bladder cancer (NMIBC). We summarize the current literature to assist in treatment decisions in… read more here.
Keywords: risk; high risk; bacillus calmette; calmette rin ... See more keywords